Clinicaltrials.gov identifier:
NCT04486352
Treatment
This study is for people with recurrent endometrial cancer
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email at ClinicalTrials.Queries@alliancefoundationtrials.org
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
About the Study
This study is to test the safety and effectiveness of different kinds of with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer. Participants will be placed into study groups based on their tumor.
What the Study Entails
The study involves 6 groups:
Group 1:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and bevacizumab (Avastin) intravenously every two weeks of the 28-day cycle.
Group 2:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Ipatasertib orally once daily for 21 days of the 28-day cycle.
Group 3:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and (or ) orally once daily for every day of the 28-day cycle.
Group 4:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Trastuzumab emtansine (or Kadcyla) intravenously on Day 1 of each 21-day cycle.
Group 5:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Tiragolumab intravenously on Day 1 of each 28-day cycle.
Group 6:
Participants will receive Inavolisib and Lentrozole (or Femara) orally once daily for every day of the 28-day cycle.
Study Sites
California
- Duarte
City of Hope Comprehensive Cancer Center
Contact: Daphne Stewart - San Francisco
UCSF Helen Diller Family Comprehensive Center
Contact: Edwin Alvarez
District of Columbia
- District of Columbia
Medstar Georgetown Cancer Institute
Contact: Ebony Hoskins
Florida
- Miami Beach
Mount Sinai Comprehensive Cancer Center
Contact: Brian Slomovitz
Illinois
- Chicago
University of Chicago
Contact: John Moroney
Massachusetts
- Boston
Dana Farber Cancer Institute
Contact: Joyce Liu
Minnesota
- Minneapolis
University of Minnesota
Contact: Britt Erickson
Missouri
- Saint Louis
Washington University School of Medicine Siteman Cancer Center
Contact: Premal Thaker
Nebraska
- Omaha
Nebraska Methodist Hospital
Contact: Brent Tierney
New Jersey
- Englewood
Englewood Health
Contact: Nimesh Nagarsheth - Morristown
Atlantic Health Systems/Morristown Medical Center
Contact: Nana Tchabo
New York
- Buffalo
Roswell Park
Contact: Peter Frederick - New York
Weill Cornell Medicine
Contact: Evelyn Cantillo
North Carolina
- Durham
Duke University Cancer Center
Contact: Angeles Alvarez Secord
Oregon
- Portland
Providence Portland Cancer Institute
Contact: Christopher Darus
Pennsylvania
- Pittsburgh
University of Pittsburgh Medical Center
Contact: Alexander B. Olawaiye
Tennessee
- Memphis
Baptist Memorial Hospital
Contact: David Engle
Women 18 years or older who:
- have a life expectancy of more than 12 weeks
- have recovered from effects of recent chemotherapy, radiation, or surgery
- have a tumor sample
- have recurrent endometrial cancer which has recurred after at least one but no more than two prior forms of therapy
Patients with:
- other invasive cancers within the last five years
- an active or history of autoimmune disease or immune deficiency
- active tuberculosis
- have significant heart disease
- have received a live vaccine in the last four weeks
- have had a severe infection within the last four weeks
- have had prior bone marrow transplant or antibiotic medication through the vein within the past four weeks
- More exclusion criteria found on clinicaltrials.gov